Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Dicerna, Roche, RXi, and More


Title: Compositions and Methods for Immunostimulatory RNA Oligonucleotides

Patent Number: 8,815,503

Filed: Sept. 14, 2006

Lead Inventor: Gunther Hartmann, University of Bonn

Title: Use of Regulatory Sequences for Specific, Transient Expression in Neuronal Determined Cells

Patent Number: 8,815,505

Filed: Sept. 30, 2010

Lead Inventor: Sebastien Couillard-Despres, Roche

Title: Modulation of Gene Expression Using Oligomers that Target Gene Regions Downstream of 3' UTR Regions

Patent Number: 8,815,586

Filed: April 23, 2010

Lead Inventor: David Corey, University of Texas

Title: Phagocytic Cell Delivery of RNAi

Patent Number: 8,815,818

Filed: July 17, 2009

Lead Inventor: Dmitry Samarsky, RXi Pharmaceuticals

Title: Antiviral Therapy

Patent Number: 8,815,820

Filed: March 30, 2010

Inventor: Amy Buck, University of Edinburgh

Title: Double-stranded Oligonucleotides

Patent Number: 8,815,821

Filed: Oct. 20, 2011

Inventor: Tod Woolf, Life Technologies

Title: Methods and Compositions for the Specific Inhibition of Beta-catenin by Double-stranded RNA

Patent Number: 8,815,825

Filed: Dec. 18, 2012

Lead Inventor: Bob Brown, Dicerna Pharmaceuticals

Title: Anti-microRNA Oligonucleotide Molecules

Patent Number: 8,816,060

Filed: Nov. 13. 2012

Lead Inventor: Thomas Tuschl, Rockefeller University

Title: Method to Trigger RNA Interference

Patent Number: 8,816,061

Filed: March 14, 2013

Lead Inventor: James Carrington, Oregon State University